ADC Therapeutics Reports Q4 2025 Earnings with Revenue Growth and Reduced Expenses
ADC Therapeutics (ADCT) reported Q4 2025 net product revenue of $22.3 million for ZYNLONTA, up from $16.4 million in the prior-year quarter. Full-year revenue for 2025 was $73.6 million, described as 'roughly stable.' Operating expenses decreased, and the company reported a net loss of $6.4 million for the quarter and $142.6 million for the year, both improved from 2024.
Tickers: $ADCT
Topics: cash position earnings financial performance net loss operating expenses revenue